Literature DB >> 9415025

Induction of selective anergy by toxic shock syndrome toxin-1 in CD8+ T cells.

Y X Zhao1, R Holmdahl, A Tarkowski.   

Abstract

Interferon-gamma (IFN-gamma) mRNA expression of murine splenic CD8+ T cells in response to toxic shock syndrome toxin-1 (TSST-1) was examined in vitro. In primary response to TSST-1, purified CD8+ cells expressed a low frequency of IFN-gamma mRNA and produced very little interleukin-2 (IL-2) compared with unseparated lymphocytes and purified CD4+ cells. The addition of IL-2 to the cell culture enhanced IFN-gamma mRNA expression in the CD8+ population. Upon restimulation with TSST-1, no IL-2 production and hardly any IFN-gamma mRNA expression were observed in the purified CD8+ lymphoblasts. Exogenously added IL-2 did not increase the IFN-gamma mRNA expression in purified CD8+ blasts exposed to TSST-1. In contrast, stimulation with concanavalin A induced a high frequency of IFN-gamma mRNA in purified CD8+ blasts. Moreover, TSST-1 induced strong IFN-gamma mRNA expression in unseparated T lymphoblasts and purified CD4+ populations. Interestingly, a combined immunocytochemistry and in situ hybridization technique showed a high frequency of CD8+ IFN-gamma mRNA-expressing cells in an unseparated blast population. These results demonstrate that TSST-1 induces a selective anergy within the purified CD8- T-cell compartment and that the IFN-gamma mRNA expression in CD8+ T blasts can be achieved by stimulation of unseparated T cells with TSST-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415025      PMCID: PMC1364057          DOI: 10.1046/j.1365-2567.1997.00344.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Reversal of in vitro T cell clonal anergy by IL-2 stimulation.

Authors:  B Beverly; S M Kang; M J Lenardo; R H Schwartz
Journal:  Int Immunol       Date:  1992-06       Impact factor: 4.823

2.  Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine.

Authors:  R T Gazzinelli; F T Hakim; S Hieny; G M Shearer; A Sher
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

3.  Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo.

Authors:  H R MacDonald; S Baschieri; R K Lees
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

4.  Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules.

Authors:  T Uchiyama; T Tadakuma; K Imanishi; M Araake; S Saito; X J Yan; H Fujikawa; H Igarashi; N Yamaura
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

5.  Toxin involvement in toxic shock syndrome.

Authors:  B A Crass; M S Bergdoll
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

6.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

7.  Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B.

Authors:  Y Kawabe; A Ochi
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

Review 8.  The staphylococcal enterotoxins and their relatives.

Authors:  P Marrack; J Kappler
Journal:  Science       Date:  1990-05-11       Impact factor: 47.728

9.  Stimulation of T cells and induction of interferon by toxic shock syndrome toxin 1.

Authors:  V V Micusan; M Desrosiers; J Gosselin; G Mercier; D Oth; A R Bhatti; H Heremans; A Billiau
Journal:  Rev Infect Dis       Date:  1989 Jan-Feb

10.  V beta-specific stimulation of human T cells by staphylococcal toxins.

Authors:  J Kappler; B Kotzin; L Herron; E W Gelfand; R D Bigler; A Boylston; S Carrel; D N Posnett; Y Choi; P Marrack
Journal:  Science       Date:  1989-05-19       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.